Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

Benzinga Newsdesk www.benzinga.com Negative 91.1%

Neg 91.1% Neu 0% Pos 0%

Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.